Graybug Vision, Inc. (NASDAQ:GRAY – Get Free Report) shares were up 2.3% during trading on Monday . The company traded as high as $3.10 and last traded at $3.08. Approximately 15,997 shares traded hands during mid-day trading, an increase of 639% from the average daily volume of 2,165 shares. The stock had previously closed at $3.01.
Graybug Vision Price Performance
The firm has a 50-day moving average of $3.10 and a 200-day moving average of $2.25. The stock has a market cap of $4.84 million, a PE ratio of -1.78 and a beta of 1.20.
Graybug Vision Company Profile
Graybug Vision, Inc, a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema.
Featured Articles
- Five stocks we like better than Graybug Vision
- Industrial Products Stocks Investing
- Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300
- Earnings Per Share Calculator: How to Calculate EPS
- Cathie Wood Buys Alibaba and Baidu: Momentum or More Value Ahead?
- How to find penny stocks to invest and trade
- This ETF Weeds Out Small-Cap Underperformers
Receive News & Ratings for Graybug Vision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graybug Vision and related companies with MarketBeat.com's FREE daily email newsletter.
